IBRX vs KEY · rev $113.3M vs P/E 13, rev $7.51B
Immunitybio Inc (IBRX) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
KeyCorp (KEY) is a banks - regional company listed on US.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
IBRX currently screens at market cap $7.88B. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the IBRX and KEY stock pages for the full models.
Not investment advice.